[A case of non-Hodgkin's lymphoma presenting optic neuropathy induced by vincristine]. 1984

K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga

UI MeSH Term Description Entries
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D009901 Optic Nerve Diseases Conditions which produce injury or dysfunction of the second cranial or optic nerve, which is generally considered a component of the central nervous system. Damage to optic nerve fibers may occur at or near their origin in the retina, at the optic disk, or in the nerve, optic chiasm, optic tract, or lateral geniculate nuclei. Clinical manifestations may include decreased visual acuity and contrast sensitivity, impaired color vision, and an afferent pupillary defect. Cranial Nerve II Diseases,Foster-Kennedy Syndrome,Optic Disc Disorders,Optic Disk Disorders,Optic Neuropathy,Second Cranial Nerve Diseases,Cranial Nerve II Disorder,Neural-Optical Lesion,Disc Disorder, Optic,Disk Disorder, Optic,Disorder, Optic Disc,Foster Kennedy Syndrome,Lesion, Neural-Optical,Neural Optical Lesion,Neural-Optical Lesions,Neuropathy, Optic,Optic Disc Disorder,Optic Disk Disorder,Optic Nerve Disease,Optic Neuropathies,Syndrome, Foster-Kennedy
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
July 2008, Neurotoxicology,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
January 2012, Case reports in ophthalmological medicine,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
September 1987, Neurology,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
August 2006, Clinical oncology (Royal College of Radiologists (Great Britain)),
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
May 1991, Cancer,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
March 1989, Indian journal of cancer,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
June 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
June 1986, [Rinsho ketsueki] The Japanese journal of clinical hematology,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
January 2013, Iranian journal of pediatric hematology and oncology,
K Hashimoto, and S Akagawa, and I Takashimizu, and A Tamura, and T Kubota, and N Murota, and M Tanoue, and H Momoi, and K Mitsunaga
March 2003, Klinische Monatsblatter fur Augenheilkunde,
Copied contents to your clipboard!